WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Kawther Akram Abo-Alkassim* and Adil R. Alsaadawi

ABSTRACT

Introduction: The kidney can develop both benign and malignant neoplasms. The most deadly of all urologic cancers is renal cell carcinoma (RCC), which makes up 2% to 3% of all adult malignant neoplasms. Method: A cross-sectional study was conducted over the period from January 2017 to December 2023, which includes a retrospective analysis of 109 randomly selected patients with kidney tumors who were collected from the Pathology Departments of Ghazi Al-Harreri Surgical Specialties Teaching Hospital and the study was concluded in five months. Results: Benign cases made up 7.3% of the study population, while malignant cases accounted for 92.7%, with more malignant cases in males, a mean age of patients with malignant lesions of 51 ± 13 years, and a mean size of patients with malignant lesions of 7 ± 0.5 cm. Regarding malignant cases, most tumors were in Grade II (52.5%) and Stage III (50.5%). lymhovascular invasion is not identified in the majority of patients (76.5%). A notable proportion had perinephric fat involvement (33.0%) and necrosis or sarcomatoid or rhabdoid features identified in (33.0%). Clear cell type RCC and papillary RCC were significantly more prevalent in tumors smaller than 7 cm in size, while chromophobe RCC was more common in tumors bigger than 7 cm. Regarding benign tumors, angiomyolipomas were found in 6 out of 8 cases (75%), while oncocytomas were found in 2 cases (25%). Conclusion: Malignant tumors make up the bulk of renal tumors. Individuals under 40 were more likely to have benign tumors, while individuals over 40 were more likely to have malignant tumors. Males were more likely to have malignant tumors. The most frequent benign tumor is angiomyolipoma, and the most common malignant tumor is clear type RCC. Malignant tumors are typically larger than 7 cm, whereas benign tumors are more likely to be smaller than that.